Eligard Could Face Two Month Suspension Due To Patent Dispute
This article was originally published in The Pink Sheet Daily
Executive SummarySanofi-Aventis may halt sales of QLT's leuprolide implant until TAP's patent expires in May.
You may also be interested in...
Most requests for the FDA’s less-heralded expedited review designation are based on Phase II or earlier data, and have a greater chance of success than requests for breakthrough designation.